10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

RUNX1 Antibody (monoclonal) (M05)

Mouse monoclonal antibody raised against a partial recombinant RUNX1.
Catalog # AT3738a

Product Information

Application	WB, IHC, IF, E
Primary Accession	Q01196
Other Accession	NM_001001890
Reactivity	Human
Host	mouse
Clonality	monoclonal
Isotype	IgG2b Kappa
Clone Names	4E8
Calculated MW	48737

Additional Information

Gene ID	861
Other Names	Runt-related transcription factor 1, Acute myeloid leukemia 1 protein, Core-binding factor subunit alpha-2, CBF-alpha-2, Oncogene AML-1, Polyomavirus enhancer-binding protein 2 alpha B subunit, PEA2-alpha B, PEBP2-alpha B, SL3-3 enhancer factor 1 alpha B subunit, SL3/AKV core-binding factor alpha B subunit, RUNX1, AML1, CBFA2
Target/Specificity	RUNX1 (NP_001001890.1, 210 a.a. ~ 310 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution	WB~~1:500~1000 IHC~~1:100~500 IF~~1:50~200 E~~N/A
Format	Clear, colorless solution in phosphate buffered saline, pH 7.2 .
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Precautions	RUNX1 Antibody (monoclonal) (M05) is for research use only and not for use in diagnostic or therapeutic procedures.


Background

Core binding factor (CBF) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters. The protein encoded by this gene represents the alpha subunit of CBF and is thought to be involved in the development of normal hematopoiesis. Chromosomal translocations involving this gene are well-documented and have been associated with several types of leukemia. Three transcript variants encoding different isoforms have been found for this gene.


References

Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer. Huang SP, et al. BJU Int, 2010 Aug 24. PMID 20735389.Therapy-related, mixed phenotype acute leukemia with t(1;21)(p36;q22) and RUNX1 rearrangement. Yamamoto K, et al. Cancer Genet Cytogenet, 2010 Sep. PMID 20682397.Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. Rocquain J, et al. BMC Cancer, 2010 Aug 2. PMID 20678218.Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Stender JD, et al. Mol Cell Biol, 2010 Aug. PMID 20547749.


Images



Antibody Reactive Against Recombinant Protein.Western Blot detection against Immunogen (36.85 KDa) .





RUNX1 monoclonal antibody (M05), clone 4E7 Western Blot analysis of RUNX1 expression in Hela S3 NE ((Cat # AT3738a)




RUNX1 monoclonal antibody (M05), clone 4E7. Western Blot analysis of RUNX1 expression in NIH/3T3 ((Cat # AT3738a)

Immunoperoxidase of monoclonal antibody to RUNX1 on formalin-fixed paraffin-embedded human placenta. [antibody concentration 3 ug/ml]





Immunofluorescence of monoclonal antibody to RUNX1 on HeLa cell. [antibody concentration 10 ug/ml]



Detection limit for recombinant GST tagged RUNX1 is approximately 1ng/ml as a capture antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.